Henry Brodaty and Alice Powell on cognitive r...

For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurology, Deputy Editor Laura Hart speaks with Professor Marjo van der Knaap (Amsterdam ...  Show more

In this episode, Heather Brown, Senior Editor at The Lancet Neurology, chats with Jan Lünemann (University of British Columbia, Canada) and Christian Münz (University of Zürich, Switzerland) about their Rapid Review on Epstein-Barr virus (EBV) and multiple sclerosis (MS). EBV, a ...  Show more

Dr. Matthew Barrett talks with Dr. Michael S. Okun about the caution and deliberation needed in understanding Parkinson disease biomarkers. Read the related viewpoint piece in JAMA Neurology. Disclosures can be found at Neurology.org. 

We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-c ...

Dr. Andy Southerland talks with Dr. Lidia Moura about the implications of large language models (LLMs) for neurologic care. Read the related article in Neurology. Disclosures can be found at Neurology.org. 

Dr. Jason Crowell talks with Prof. Bastiaan Bloem about the latest developments in biomarkers and treatments for movement disorders, which have been described in numerous research papers from 2022. 

Read the related article in <a href= "https://www.thelancet.com/journal ...